Tamoxifen therapy and carcinogenic risk.

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Journal of the National Cancer Institute

• Publication date

  1995-09-20

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1093/JNCI/87.18.1343PMID 7658489
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Royal Marsden Hospital pilot tamoxifen chemoprevention trial

  2004cited by this paper
• Discovering the truth about tamoxifen: problems of multiplicity in statistical evaluation of biomedical data.

  1995cited by this paper
• DNA damage as assessed by 32P-postlabelling in three rat strains exposed to dietary tamoxifen: the relationship between cell proliferation and liver tumour formation.

  1995cited by this paper
• Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group.

  1995cited by this paper
• Population-based study of tamoxifen therapy and subsequent ovarian, endometrial, and breast cancers.

  1995cited by this paper
• Species differences in the covalent binding of [14C]tamoxifen to liver microsomes and the forms of cytochrome P450 involved.

  1995cited by this paper
• Tamoxifen and tumorigenicity: a predictable concern.

  1995cited by this paper
• Hormone replacement therapy and endometrial cancer risk: a meta-analysis.

  1995cited by this paper
• 32P-postlabelled DNA adducts in liver obtained from women treated with tamoxifen.

  1995cited by this paper
• Reduced genotoxicity of [D5-ethyl]-tamoxifen implicates alpha-hydroxylation of the ethyl group as a major pathway of tamoxifen activation to a liver carcinogen.

  1994cited by this paper
• DNA adduct formation by tamoxifen with rat and human liver microsomal activation systems.

  1994cited by this paper
• Risk of endometrial cancer after tamoxifen treatment of breast cancer.

  1994cited by this paper
• Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.

  1994cited by this paper
• Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD(BR) rats.

  1993cited by this paper
• Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats.

  1993cited by this paper
• The Scottish trial of adjuvant tamoxifen in node-negative breast cancer. Scottish Cancer Trials Breast Group.

  1992cited by this paper
• Induction of covalent DNA adducts in rodents by tamoxifen.

  1992cited by this paper
• Genotoxic potential of tamoxifen and analogues in female Fischer F344/n rats, DBA/2 and C57BL/6 mice and in human MCL-5 cells.

  1992cited by this paper
• Metabolites, pharmacodynamics, and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient.

  1991cited by this paper

• Differential Effects Of Estradiol And Tamoxifen On Pyrrolidon Carboxypeptidase Activity In The Human Estrogen-dependent And Estrogen-independent Breast Cancer Cell Lines MCF-7 And EVSA-T

  2010cites this paper
• Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial.

  2007cites this paper
• Immunohistochemical expression of steroid receptors and glycodelin A in isolated proliferative human endometrial glandular cells after stimulation with tamoxifen and phytoestrogens (genistein and daidzein).

  2003cites this paper
• Measurement of markers for breast cancer in a model system using laser scanning cytometry.

  2000cites this paper
• A brief review of the breast cancer prevention trials.

  2000cites this paper
• Hysteroscopic evaluation of the endometrium of post‐menopausal patients with breast cancer before and after tamoxifen use

  1999cites this paper
• The tamoxifen dilemma.

  1999cites this paper
• A meta-analysis of hormone replacement therapy and colon cancer in women.

  1998cites this paper
• Variation in endometrial thickening in women with amenorrhea on tamoxifen

  1998cites this paper
• The effects of norethisterone on endometrial abnormalities identified by transvaginal ultrasound screening of healthy post-menopausal women on tamoxifen or placebo.

  1998cites this paper
• Behaviour of vaginal epithelial maturation and sex hormone binding globulin in post‐menopausal breast cancer patients during the first year of tamoxifen therapy

  1998cites this paper
• Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial.

  1998cites this paper
• Virilizing ovarian tumor of low malignant potential associated with antecedent tamoxifen use for breast cancer.

  1998cites this paper
• The metabolism and genotoxicity of tamoxifen.

  1997cites this paper
• Inhibition of proliferation of estrogen receptor-negative MDA-MB-435 and -positive MCF-7 human breast cancer cells by palm oil tocotrienols and tamoxifen, alone and in combination.

  1997cites this paper
• Acute leukaemia during tamoxifen therapy

  1997cites this paper
• Tamoxifen and Secondary Tumours

  1997cites this paper
• Plant-derived anticancer agents.

  1997cites this paper
• Screening for cancer in high-risk families.

  1996cites this paper
• Transvaginal sonographic and hysteroscopic findings in postmenopausal women receiving tamoxifen.

  1996cites this paper
• Carcinogenicity of Tamoxifen

  1996cites this paper
• Screening for cancer in high risk families.

  1995cites this paper